In continuation of its commitment to Multiple Sclerosis (MS) patients in India, Biogen Idec has introduced Tysabri (natalizumab), the first humanized, monoclonal antibody for the treatment of relapsing and remitting MS in India.
Tysabri inhibits adhesion molecules on the surface of immune cells. Research suggests that it works by preventing immune cells from migrating from the bloodstream into the brain where they can cause inflammation and potentially damage nerve fibres and their insulation.
MS is a chronic, progressive, and unpredictable inflammatory disease of the Central Nervous System (CNS). It primarily affects people between 20-40 age group and is seen more frequently in women than men. In India, the exact number of MS patients is unknown. MS is an autoimmune disease, meaning a person’s natural defence system mistakenly attacks healthy cells in the body.........Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905